Patent US3403548A successfully refreshed from Google Patents.
Patent US4032659A successfully refreshed from Google Patents.
US4032659A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of viral chemoprophylaxis
Assignee: Wyeth LLC
•
Filing: 1975-06-26
•
Granted: 1977-06-28
•
Expires: 1995-06-26
Abstract
Abstract It has been found that compounds having a stereochemically unencumbered access to a nitrogen-nitrogen bond have antiviral activity in extremely low dose ranges. Hydrazine, hydrazine derivatives and related compounds have been found to be active in protecting animals against disease caused by both DNA and RNA type viruses at doses of about 250 picograms to 250 micrograms per kilograms of host body weight.
Inventors
- 👤 Charles Paul Hegarty
- 👤 Helen C. Pietryk
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 19:36
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/02; A61K31/00; A61K31/13; A61K31/15; A61K31/33; A61K31/395; A61K31/495; A61K31/50; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
132 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is a member of the class consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound is selected from the class consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. acetoacetic acid, ethylester, thiosemicarbazone F. cyclohexanone, thiosemicarbazone G. cyclobutanone, thiosemicarbazone H. 2-indanone, thiosemicarbazone I. 2-indanone, 4-allythiosemicarbazone J. cyclopentanone, o-tolylthiosemicarbazone K. adamantyl thiosemicarbazide L. thiosemicarbazide M. methisazone N. semicarbazide and the pharmaceutically acceptable acid addition salts thereof.
Claim 2
Independent Claim
132 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is a member of the class consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound is selected from the class consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. acetoacetic acid, ethylester, thiosemicarbazone F. cyclohexanone, thiosemicarbazone G. cyclobutanone, thiosemicarbazone H. 2-indanone, thiosemicarbazone I. 2-indanone, 4-allythiosemicarbazone J. cyclopentanone, o-tolylthiosemicarbazone K. adamantyl thiosemicarbazide L. thiosemicarbazide M. methisazone N. semicarbazide and the pharmaceutically acceptable acid addition salts thereof.
Claim 3
Dependent Claim
14 words
A method as defined in claim 1 in which the compound is administered orally.
Claim 4
Dependent Claim
22 words
A method as defined in claim 1 in which the compound is administered in the form of a tablet, capsule or solution.
Claim 5
Dependent Claim
17 words
A method as defined in claim 1 in which the compound is administered at 48 hour intervals.
Claim 6
Dependent Claim
24 words
A method as defined in claim 1 in which the compound is administered either before or after infection or both before and after infection.
Claim 7
Independent Claim
110 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is selected from the group consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound selected from the group consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. cyclohexanone, thiosemicarbazone F. cyclobutanone, thiosemicarbazone G. cyclopentanone, o-tolylthiosemicarbazone and the pharmaceutically acceptable acid addition salts thereof.
Claim 8
Independent Claim
110 words
A method of controlling a virus infection in a host suffering from a virus infection in which the virus is selected from the group consisting of Herpes simplex, Vaccinia, Influenza A (PR8), Influenza A 1 (Ann Arbor), Influenza A 2 (Taiwan), Influenza B (Mass.), Influenza B (Maryland), Mengo, Columbia SK polio, and Neurovaccinio comprising orally administering to the animal host from 250 picograms to 250 micrograms per kilogram of host body weight of a compound selected from the group consisting of: A. 2-butanone, thiosemicarbazone B. 3-pentanone, thiosemicarbazone C. 2-pentanone, thiosemicarbazone D. acetone, thiosemicarbazone E. cyclohexanone, thiosemicarbazone F. cyclobutanone, thiosemicarbazone G. cyclopentanone, o-tolylthiosemicarbazone and the pharmaceutically acceptable acid addition salts thereof.
Claim 9
Dependent Claim
14 words
A method as defined in claim 6 in which the compound is administered orally.
Claim 10
Dependent Claim
22 words
A method as defined in claim 6 in which the compound is administered in the form of a tablet, capsule or solution.
Claim 11
Dependent Claim
17 words
A method as defined in claim 6 in which the compound is administered at 48 hour intervals.
Claim 12
Dependent Claim
24 words
A method as defined in claim 6 in which the compound is administered either before or after infection or both before and after infection.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-27 | 1980-12-27 | 1981-06-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-27 | 1984-12-27 | 1985-06-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-27 | 1988-12-27 | 1989-06-28 | $7700.00 | Window Closed / Lapsed |